NCT01585766 - Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2012

Primary Completion Date

January 2, 2015

Study Completion Date

June 20, 2016

Conditions

Multiple Sclerosis, Relapsing Forms

Interventions

DRUG

MEDI-551 30 MG-IV

Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.

DRUG

MEDI-551 60 MG-SC

Participants received SC injection of 60 mg MEDI-551 on Day 1.

DRUG

PLACEBO-IV-SC

Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1

DRUG

MEDI-551 100 MG-IV

Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.

DRUG

MEDI-551 300 MG-SC

Participants received SC injection of 300 mg MEDI-551 on Day 1.

DRUG

MEDI-551 600 MG-IV

Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.

Trial Locations (16)

Research Site, Scottsdale

Research Site, Long Beach

Research Site, Sacramento

Research Site, Denver

Research Site, Tampa

Research Site, Marlton

Research Site, Winston-Salem

Research Site, Cordova

Research Site, Houston

Research Site, Katowice

Research Site, Szczecin

Research Site, Barcelona

Research Site, Girona

Research Site, Seville

Research Site, Donetsk

Research Site, Kyiv